Panbela Therapeutics (PBLA) Q2 2024 earnings summary

Executive summary

• The Phase III ASPIRE trial for ivospemin in metastatic pancreatic cancer continues after a positive DSMB safety review, with enrollment progressing faster than anticipated and full enrollment expected by Q1 2025; interim analysis is delayed to early 2025 due to prolonged patient survival, suggesting potential efficacy benefit.

• The company maintains commitment to FAP and PACES programs, with PACES phase III trial enrollment completed and data readout expected in H2 2026.

• Monetization of the eflornithine pediatric neuroblastoma program continues, with $775,000 received and further milestone payments possible; the program is FDA approved and commercialized by US WorldMeds.

• Multiple phase II and I trials are underway or planned in prostate cancer, type 1 diabetes, ovarian cancer, and non-small cell lung cancer, with preclinical collaborations focusing on the polyamine pathway and CAR T-cell therapy.

• The company’s common stock was delisted from Nasdaq in April 2024 and is now quoted on OTCQB; relisting efforts are ongoing.

Financial highlights

• Q2 2024 net loss was $7.1 million ($1.47 per diluted share), compared to $5.8 million ($159.15 per diluted share) in Q2 2023, with operating expenses rising to $8.1 million and R&D expenses increasing 65.3% to $7.0 million, while G&A expenses decreased 32.7% to $1.1 million.

• Cash as of June 30, 2024, was $59,000, with total current assets of $0.8 million and current liabilities of $16.8 million, resulting in a current ratio of approximately 0.05.

• Net cash used in operating activities for the first half of 2024 was $10.4 million, down from $15.5 million in the prior year period.

• The company raised $8.1 million from a public offering in January 2024 and made $1.0 million in loan repayments.

• Stockholders' deficit was $10.6 million at June 30, 2024.

Outlook and guidance

• Full enrollment for the ASPIRE trial is projected for Q1 2025, with interim analysis expected in early 2025 due to longer-than-expected patient survival.

• PACES phase III data readout is anticipated in H2 2026.

• The company needs to raise additional capital immediately to continue operations and execute its business plan, including clinical trials and regulatory submissions.

• Multiple clinical milestones are targeted for H2 2024, including trial initiations and regulatory feedback.